Kenvue Q4 Earnings Beat Expectations as Kimberly-Clark Acquisition Progresses

Kenvue delivered impressive fourth-quarter results that surpassed analyst forecasts on both top and bottom lines, while advancing toward its transformative acquisition by Kimberly-Clark. The consumer health company reported adjusted earnings of 27 cents per share, topping the Zacks Consensus Estimate of 22 cents, with total revenues reaching $3.78 billion against expectations of $3.71 billion. The strong finish to fiscal 2025 reflects the company’s operational discipline and pricing effectiveness, even as it navigates toward integration with Kimberly-Clark under a definitive merger agreement.

Performance was fueled by organic sales growth of 1.2%, driven primarily by favorable pricing and value realization of 2.3%, though volume declines of 1.1% and seasonal softness in North America weighed on results. The 3.2% year-over-year revenue increase benefited from a 2.1% foreign currency tailwind alongside the organic expansion. Geographic strength in Asia Pacific, Latin America, and Europe, the Middle East and Africa (EMEA) provided crucial offsets to North American weakness, underscoring the company’s global diversification as it prepares for the Kimberly-Clark combination.

Financial Performance Tops Market Forecasts

Kenvue’s revenue surge of $3.78 billion reflected solid execution across pricing strategies and product mix enhancement. The year-over-year comparison benefited from comparing against the prior year’s supply chain disruptions in Asia Pacific. However, customer inventory reductions and subdued U.S. seasonal demand—typically a strong quarter for over-the-counter health products—created headwinds that limited volume expansion. Adjusted earnings growth to 27 cents per share from 26 cents in the prior year demonstrated the company’s ability to improve bottom-line performance despite operating challenges.

The organic sales growth of 1.2%, while modest, underscores the premium positioning of Kenvue’s portfolio. Value realization of 2.3% indicates successful price increases on core categories, compensating for the 1.1% volume pressure. This dynamic positioning will be strategically important for the Kimberly-Clark integration, as the combined entity will leverage pricing power across a broader consumer portfolio.

Margin Expansion Driven by Supply-Chain Excellence

Operational leverage emerged as a key strength, with adjusted gross profit climbing 3.4% year-over-year to $2.22 billion, while gross margins expanded by 10 basis points to 58.8%. This improvement reflects productivity gains from global supply-chain optimization and favorable product mix, which helped absorb inflationary pressures, tariff impacts, and transactional foreign exchange headwinds. The Vue Forward initiative contributed meaningfully to cost discipline, providing important efficiency gains as the company prepares for structural changes ahead.

SG&A expenses rose modestly by 0.7% year-over-year to $1.54 billion, but as a percentage of revenues contracted 100 basis points to 40.6%, demonstrating improved leverage on operating expenses. Adjusted operating income reached $751 million, up 7% from the prior year, with operating margins expanding 70 basis points to 19.9%. These improvements signal that despite higher brand support investments, the company has achieved meaningful operational efficiencies. Adjusted EBITDA of $815 million, up 2.9% year-over-year, maintained margins at 21.6%, reflecting stable operational performance throughout the quarter.

Segment Performance Shows Mixed Regional Dynamics

Self Care Category Results: Net sales of $1.59 billion exceeded consensus estimates of $1.58 billion, though organic sales declined 1.2% due to a 3.1% volume drop partially offset by 1.9% value realization gains. The category faced significant seasonal headwinds from low flu incidence and reduced consumer engagement in the United States, which declined year-over-year. Despite these pressures, Kenvue maintained slight market share gains in seasonal businesses through innovation leadership, with Tylenol showing improved consumption and share trends in December following a late-quarter flu surge. International markets provided brighter spots, with organic sales rebounding in Asia Pacific and growing across major need states in EMEA.

Skin Health and Beauty Performance: This segment drove growth with net sales of $1.04 billion, surpassing the consensus estimate of $1.03 billion. Organic sales growth of 1.5%, supported by 2.3% value realization gains tempered by 0.8% volume pressure, demonstrated pricing power in premium categories. Strong commercial execution and continuous innovation outside North America propelled geographic expansion, with all regions outside North America contributing to organic growth.

Essential Health Leadership: The strongest segment, Essential Health recorded net sales of $1.15 billion, exceeding estimates of $1.11 billion with robust organic growth of 4.2%. Value realization of 2.9% combined with volume growth of 1.3% created a positive double-barrel effect. Broad-based growth across major need states, led by Asia Pacific, Latin America, and EMEA with sequential North American improvement, positioned this segment as a cornerstone for future Kimberly-Clark combined operations.

Regional Performance Reveals Geographic Divergence

Geographic performance underscores both challenges and opportunities as Kenvue approaches its transformation. North America net sales declined 4.5% to $1.76 billion, reflecting the challenging U.S. seasonal environment and inventory normalization. Conversely, international markets delivered impressive expansion. EMEA surged 10% to $949 million, Asia Pacific climbed 10.7% to $703 million, and Latin America led growth with a 14.6% increase to $369 million. This international momentum provides strategic advantages for the combined Kimberly-Clark entity, which will inherit a stronger global footprint with established presence in high-growth markets.

Balance Sheet Strength Supports Strategic Transition

Kenvue concluded fiscal 2025 with solid financial positioning suitable for the upcoming integration. Cash and cash equivalents totaled $1.1 billion, while total debt stood at $8.5 billion. Operating cash flow of $2.2 billion for the year improved from $1.8 billion in the prior year, demonstrating enhanced working capital management. With capital expenditures of $0.5 billion, the company generated free cash flow of $1.7 billion, up from $1.3 billion previously, providing financial flexibility during the Kimberly-Clark transition period. This robust cash generation supports the company’s ability to maintain operations and service obligations as regulatory approvals and closing conditions progress.

Kimberly-Clark Deal Moves Toward Completion

The transformative acquisition by Kimberly-Clark represents a major inflection point for Kenvue’s trajectory. On November 2, 2025, the companies entered a definitive merger agreement whereby Kimberly-Clark will acquire all outstanding Kenvue shares through a cash-and-stock transaction. Shareholders of both companies delivered overwhelming approval at their Special Meetings on January 29, 2026. The Hart-Scott-Rodino Antitrust Improvements Act waiting period expired on February 4, 2026, clearing a significant regulatory hurdle. The transaction is expected to close in the second half of 2026, pending receipt of required foreign regulatory approvals and satisfaction of customary closing conditions outlined in the merger agreement.

This transaction reflects strategic recognition by Kimberly-Clark of Kenvue’s market positioning, pricing power, and international growth trajectory. The combination will create substantial synergies through portfolio optimization, supply chain consolidation, and accelerated innovation across the combined consumer health and hygiene platform.

Investment Perspective

Kenvue’s strong Q4 performance—with earnings beating estimates by 23%, revenues exceeding forecasts by $69 million, and operating margin expansion despite cost inflation—demonstrates operational excellence heading into its Kimberly-Clark integration. The company achieved this while maintaining brand investments and navigating seasonal challenges, suggesting management’s confidence in strategic positioning. As the deal progresses through final regulatory approvals, Kenvue’s demonstrated ability to drive organic growth through pricing, expand margins through operational efficiency, and generate substantial free cash flow will be critical assets to the combined organization under Kimberly-Clark’s ownership.